MitoSense, Inc.
MitoSense, Inc. is a research and development company focused on developing treatments for neurodegenerative diseases through innovative mitochondrial therapies. With exclusive licensing of Mitochondria Organelle Transplantation (MOT™) technology, MitoSense aims to improve the lives of patients suffering from conditions such as ALS, Alzheimer's, and Parkinson's disease.
Industries
Nr. of Employees
small (1-50)
Products
Patent-pending mitochondrial organelle transplantation technology
A patent-pending methodology for transferring intact mitochondria into recipient cells to restore mitochondrial function, demonstrated in cell culture, animal models, and early human application.
Patent-pending mitochondrial organelle transplantation technology
A patent-pending methodology for transferring intact mitochondria into recipient cells to restore mitochondrial function, demonstrated in cell culture, animal models, and early human application.
Expertise Areas
- Mitochondrial therapeutics
- Neurodegenerative disease research (ALS, Parkinson's, Alzheimer's, Huntington's)
- Translational research and preclinical development
- Organelle and cell transplantation techniques
Key Technologies
- Organelle (mitochondrial) transplantation
- Mitochondrial isolation from donor cells
- Cryopreservation of donor cells (fibroblasts, mesenchymal stem cells)
- Cell culture assays and in vitro models
Key People
Investors
Caydan Capital Partners
$3,500,000 funded.
Announced on 2024-01-22.
Caydan Capital Partners
$3,500,000 funded.
Announced on 2024-01-22.
News & Updates
MitoSense Inc. announces the publication of a study on alternative mitochondrial donors.
MitoSense supports a benefit concert aimed at raising awareness for ALS and TBI.
MitoSense announces its participation in the Military Health System Research Symposium.
MitoSense has been accepted into the NVIDIA Inception Program, marking a significant milestone for the company.
MitoSense Inc. announces the publication of a study on alternative mitochondrial donors.
MitoSense supports a benefit concert aimed at raising awareness for ALS and TBI.
MitoSense announces its participation in the Military Health System Research Symposium.
MitoSense has been accepted into the NVIDIA Inception Program, marking a significant milestone for the company.